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POINT‐BY‐POINT REPLY TO REFEREE NO. 1 
 
The reviewer formulated a series of major concerns 
Major point 1 raised by reviewer 1: Little data are presented concerning the function of AIF2. Does 
AIF2 fulfill redox function in normal cells, similarly to AIF1? Does AIF2 play a role in cell death?  
Our response: We have addressed the question as to whether AIF2 is as efficient as AIF1 in restoring 
the function of complex 1 in AIF-deficient cells. The results of these experiments are shown in Figure 
6d. It should be noted that the respiratory and redox functions of AIF are closely linked because redox-
deficient AIF mutants are unable to restore the abundance and function of respiratory chain complex I 
from AIF knockout cell (Urbano, A. et al. (2005) EMBO J. 24, 2815–2826), as we have discussed in 
the text page 10, lines 15 to 20. As a result, it appears that AIF2 has a normal redox function, similar 
to that of AIF1. As to the second question formulated by the reviewer ("Does AIF2 play a role in cell 
death?"), we are confronted with the problem that none of the cell lines that we characterized 
predominantly expressed AIF2 (although, based on the in situ hybridization studies, a sizeable fraction 
of primary brain cells solely express AIF2, not AIF1). Therefore, we cannot address the reviewer's 
excellent question experimentally at this point, and we have to wait for the results of the knockout 
experiments in which exon 2b (which is specific for AIF2) has been flanked by lox sites and will be 
excised enzymatically by tissue-specific expression of the Cre recombinase. Although we have 
managed to generate mice expressing a floxed exon 2b, it will take us at least six months to generate 
tissue-specific (and in particular brain-specific) AIF2 knockout mice and to characterize their 
propensity to cell death. Therefore, it is impossible to furnish clearcut results on the putative pro- or 
anti-apoptotic functions of AIF2 within the rigid time frame established by CDD (which asks us to 
resubmit our paper within four months).  
 
Major point 2 raised by reviewer 1: The authors propose that AIF2 is retained in mitochondria to 
minimize its neurotoxic effects. Therefore, it would be interesting to compare the oxidation of 
NAD(P)H by AIF1 versus AIF2. Since AIF2 retains in mitochondria, this critical experiment could 
reveal whether AIF2 is more important for fulfilling the redox function rather than cell death. 
Measurement of cell death in the presence or absence of AIF2 (by using the siRNA against 
AIFexon2a) would also answer this question.  
Our response: We have knocked down AIF2 using a siRNA in SHSY-5Y neuroblastoma cells that 
express both AIF1 and AIF2, and we have found that this manipulation did not affect the baseline 
NAD(P)H levels, as determined by assessing the autofluorescence of cells. In line with the report 
published by Churbanova et al. (Redox-dependent changes in molecular properties of mitochondrial 
apoptosis-inducing factor. J Biol Chem 2008; 283: 5622-5631), showing that the NAD(P)H oxidase  
activity of AIF is very low, our observation suggests that AIF may serve in a local redox signaling 
function that is yet to be determined. These data have been included in the paper, following the 
reviewer's suggestion (supplemental Figure 3) and have been commented on in the text (page 10, lines 
21 to 23; page 11, lines 1 to 3). 
 
Major point 3 raised by reviewer 1:  Fig. 5d. After expression of AIF 3'UTR siRNA an additional 
band (the size lower than endo-AIF) is appeared. What is the source of this band?  
Our response: These experiments have been repeated several times, leading to the conclusion that the 
additional band results from the overexposure of the autoradiographic film. We have replaced the 
figure accordingly and in the revised manuscript Fig. 5d is now Fig.6d 
 
Major point 4 raised by reviewer 1: Amount of VDAC in all transfected cells after treatment with 
detergent is increasing in both pellet and supernatant (Fig. 7a). How it is possible?  
Our response: Driven by the reviewer’s constructive critique, we have repeated the VDAC immunoblot 
detection in conditions in which the amount of cell lysate (antigen) and also the concentration of the 
secondary antibody were rigorously standardized (Fig. 7A). We suspect that the result that perturbed 
the reviewer was due to the overexposure of the membrane (which can lead to the paradoxical 
reduction in the intensity of band, in particular in the center of the band, that corresponds to 
particularly high concentrations of the antigen+antibody complex detected with the ECL 
chemoluminescence reagent). This is well known phenomenon (cf. ECL manual).  
 
 
Major point 5 raised by reviewer 1: Since AIF2 is specific for neuronal tissues and neuroblastomas, 
it will be interesting to know whether this protein is also expressing in tumors of neuro-endocrine 
origin.  
 
Our response: We enthusiastically welcome the reviewer's suggestion that we will address in 
forthcoming papers. As it stands, adrenal tissues (which are largely of neuro-endocrine origin) do not 
express AIF2. Similarly, several melanoma cell lines (which are often deemed to be of neuro-
endocrine origin) were negative for AIF2 expression. Therefore, we estimate that it is improbable that 
AIF2 is expressed in neuro-endocrine tumors. However, this assumption has to be subjected to a 
thorough verification.  
  
In addition, the reviewer raised two minor critiques:  
Minor point 1 raised by reviewer 1: Fig 2a. Expression of AIF in brain is unexpectedly lower in 
comparison to liver and heart keeping in mind the importance of AIF-mediated cell death for neuronal 
cells. This should be discussed. Is the expression level low to reduce toxicity? Or might it be so that 
the redox function/capacity of AIF in brain is not so important as compared to in liver, heart, etc?  
Our response: Following the reviewer's recommendations, we have discussed the comparatively low 
AIF expression in brain as compared to liver and heart in the Results (page 8, lines 4 to 8). In a report 
published by Benit et al. (PLoS ONE 2008; 3: e3208), the amount of AIF protein in various murine 
organs was compared to that of another mitochondrial protein (VDAC/porin) and it was found that in 
all analyzed organs (cerebellum, spinal cord, cortex, retinas, heart, skeletal muscle, kidney and liver) 
the ratio AIF/VDAC was similar. In conclusion, these published data indicate that a low level of AIF, 
in brain compared to heart or other organs, is a sign of a lower amount of total mitochondrial proteins. 
 
Minor point 2 raised by reviewer 1: Page 7. What does mean: "the two exons were generated by 
gene duplication well before the mammalian radiation"? 
Our response: The criticized phrase on page 7 (lines 5 to 9) has been reformulated.  
“Likewise, the two exons were generated by gene duplication well before the speciation of mammals 
(data not shown). Indeed, we were able to trace the duplication event to chicken genome, where a 
region homologous to the mammalian exon 2a can be found 5' of exon 2b on chromosome 4, although 
the splice acceptor site of exon 2a seems to be non canonical (UCSC, genome browser).” 
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The reviewer formulated a series of specific points of critique: 
Specific point 1 raised by reviewer 2: AIF has to be cleaved from its membrane anchor, the 
transmembrane segment partially encoded in the alternative exons, before it can be released 
from mitochondria.  The cleavage site however appears to be located in the intermembrane 
space, hence this region is similar between AIF1 and AIF2. This suggests that cleavage 
should occur independently of the matrix located isoform specific N-terminal regions. A 
model in which the different hydrophobicities could account for different efficiencies to 
release AIF does not make sense in the light of many data on the requirement of  processing 
of AIF prior to its release from mitochondria (e.g. Polster et al. 2005, Otera  et al. 2005,…).   
 
Our response: We have carefully considered this point raised by the reviewer. Although the reviewer 
is, in principal, correct in her/his affirmation, it appears that AIF2 is more difficult to be released from 
mitochondria than AIF1. Therefore, it appears that the mitochondrial release-associated cleavage of 
AIF2 is more difficult to be achieved than AIF1. This difference cannot be explained by differences in 
the primary sequence of the cleavage site. Rather, they must be linked to other properties of the 
molecule such as the accessibility of AIF2 (which may be more profoundly "buried" in its N-terminus 
in the lipid bilayer of the inner mitochondrial membrane than AIF1). In support of this possibility, we 
would like to mention that biochemical studies of AIF1 carried out by Churbanova et al. (Redox-
dependent changes in molecular properties of mitochondrial apoptosis-inducing factor. J Biol Chem 
2008; 283: 5622-5631) suggest that redox-regulated changes in the conformation of AIF that implicate 
its N-terminal and C-terminal segments might determine the dimerization of AIF, its accessibility to 
apoptotic proteases and by consequence its mitochondrial release in dying cells. This point has been 
explicitly expressed in the revised version of the manuscript (page 12, lines17 to 23; page 13, lines 1 
to 3).  
 
Specific point 2 raised by reviewer 2:.  Experiment 7c: It is essential to show at least two 
fractions of this fractionation including the membrane (hence mitochondria containing) 
fraction. As the figure is now, it is impossible to judge whether the differences in AIF release 
stem from different expression levels (even of the normal AIF, as Figure 7b would suggest 
lower level of AIF if AIF2-FLAG is overexpressed), or whether the non released AIF is found 
in the pellet, or whether part of the AIF is found in another localization (e.g. the  nucleus).  
 
Our response: We have repeated the experiment shown in Fig. 7c, including the additional control 
requested by the reviewer. This improved experiment is now fully included in the revised version of 
the paper. As an additional control, we checked the release of another mitochondrial protein (EndoG), 
whose release was not affected by AIF1 or AIF2.  As the reviewer will appreciate, there is a clear 
difference in the mitochondrial release of AIF1 versus AIF2. We thank the reviewer for her/his elegant 
suggestion that helped to improve our paper.  
 
 
Specific point 3 raised by reviewer 2: Experiment 7d lacks controls (i.e. non precipitated 
control proteins).  
 
Our response: In accord with the reviewer’s suggestion, the whole cell lysate controls (Input) were 
clearly indicated in Fig. 7d.  
 
Specific point 4 raised by reviewer 2: It would be desirable to use one cellular model in a 
consistent way for the cell biology part of the manuscript to allow the transfer of the different 
sets of data (EM in U20S cells versus fractionation with HeLa cells).  
 
Our response: To streamline the data representation and to focus on essential facets of the paper, the 
electron microscopy results obtained on stably transfected U2OS were moved to the supplementary 
Fig. 4. This figure contains additional data obtained with the same cell line that overexpress either 
AIF1 or AIF2.  
 
Specific point 5 raised by reviewer 2:. Figure legend 7b: Na-bicarbonate should be Na-
carbonate.  
 
Our response: This error has been corrected.  
 
Specific point 6 raised by reviewer 2: 6. Can AIF2 be cleaved to the same extent by calpains 
and cathepsins as AIF1?  
 
Our response: We have attempted to generate recombinant full-length AIF1 and AIF2 (with the entire 
N-terminus) and thus far have failed to obtain a correctly folded protein. As a result, we have been 
unable to perform the requested proteolytical experiments. However, we feel the proteolysis of 
purified proteins may not reflect that of their membrane-embedded equivalents. We have discussed the 
proteolytic cleavage of AIF in the revised paper (page 12, lines17 to 23; page 13, lines 1 to 3).  
 
 
 
Specific point 7 raised by reviewer 2:. Why has expression of AIF2 a dominant negative effect 
on cristae formation and AIF accumulation (and possibly release)?  
 
Our response: We have no explanation on how AIF might affect cristae formation (although AIF 
might of course, theoretically, affect membrane curvature). As it stands, we simply report that 
ovexpressed AIF1 and overexpressed AIF2 affect the morphology of mitochondria in a clearly 
distinguishable fashion, pointing to differences between AIF1 and AIF2 (perhaps because both 
proteins impose different levels of membrane curvature). Since these data are based on the 
transfection-enforced overexpression of both isoforms, they can be criticized and have been moved to 
the supplemental section of the paper. However, we have provided a hypothetical explanation how 
AIF2 may inhibit the release of AIF1, namely by forming heterodimers (or perhaps higher-order 
hetero-oligomers). In this case, the more membrane-anchored isoform would retain the more "voluble" 
isoform in mitochondria, as we have discussed in the revised version of the paper (page 12, lines17 to 
23; page 13, lines 1 to 8).  
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The reviewer formulated one single point of critique: In this manuscript Authors perform a 
thorough characterization of AIF2, showing that it is specifically expressed in neurons and more 
tightly anchored to the inner mitochondrial membrane. The data are convincing and solid. However, 
what is really missing from the paper to be a strong candidate for CDD are the cell death 
experiments. If the Authors had an experiment of selective silencing of AIF2 in neurons, or of both 
forms with the reintroduction of a resistant AIF2 variant and then they tested the impact on neuronal 
viability/function/cell death the paper would be perfect. As it is, I see it more suited for a Journal 
where to report the characterization of a novel splice variant of an important gene, like JBC, or a 
neurobiology Journal. 
Our response: The reviewer criticized the absence of cell death experiments from our paper and 
insinuates that this would be sufficient to question the suitability of our paper for CDD. "Cell Death & 
Differentiation" has a dual scope. The journal deals with cell death mechanisms, as well as will 
mechanisms of cell differentiation. In our paper, we show that AIF is expressed in a differentiation-
dependent fashion in the developing brain of mice and humans. We show that AIF is specifically 
expressed in the brain in some particular cell types. Moreover, we show that AIF1 and AIF2 differ in 
their propensity to be released from mitochondria by a series of pharmacological and chemical 
inducers.  Therefore, we believe that our paper qualifies for publication in CDD (placing emphasis on 
the second, not the first, "D"). The reviewer requested experiments in which we would silence AIF2 in 
cells that express AIF2. These experiments have also been asked for by reviewer 1 (see points 1 and 2 
raised by this referee), and new data have been added to the paper.  
As we have explained in our point-by-point reply to reviewer 1, we are confronted with the problem 
that none of the human or murine cell lines that we characterized thus far predominantly expressed 
AIF2 (although, based on the in situ hybridization studies, a sizeable fraction of primary brain cells 
solely express AIF2, not AIF1). Therefore, we have to wait for the results of the knockout experiments 
in which exon 2b (which is specific for AIF2) has been flanked by lox sites and will be removed by 
tissue-specific expression of the Cre recombinase. Although we have been successful in generating 
mice expressing a floxed exon 2b, we will need more than six months to generate tissue-specific (and 
in particular brain-specific) AIF2 knockout mice and to characterize their susceptibility to cell death. 
Therefore, we are unable to furnish results on the putative pro- or anti-apoptotic functions of AIF2 
within the calendar established by the Nature Publishing Group for resubmission. 
To meet the reviewer’s critique, we have included additional data that show that AIF2 is upregulated 
in human mesencephalic neural progenitor cells as they differentiate in vitro into post-mitotic 
dopaminergic neurons. Our results clearly indicate that the expression level of AIF2 depends on the 
differentiation status of neuronal cells, both in the human and in the mouse systems. This finding 
suggests that our paper is optimally suitable for publication in CDD.   
END 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Running title: Brain-specific AIF2 
 
Key Words: brain development, neural differentiation, neural progenitor, neuroblastoma, 
oxidative phosphorylation 
 
Abbreviations: CNS: central nervous sytem; FISH: fluorescent in situ hybridization; LUHMES: 
Lund Human Mesencephalic neurons; IMSS: inner membrane sorting signal; MLS: 
mitochondrial localization signal; MOMP: mitochondrial outer membrane permeabilization. 
NCI: National Cancer Institute; NLS: nuclear localization signal; TEM: transmission electron 
microscopy. 
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Abstract 
 
Apoptosis-Inducing factor (AIF) plays important supportive as well as potentially lethal roles in 
neurons. Under normal physiological conditions, AIF is a vital redox-active mitochondrial 
enzyme, whereas in pathological situations, it translocates from mitochondria to the nuclei of 
injured neurons and mediates apoptotic chromatin condensation and cell death. Here, we reveal 
the existence of a brain-specific isoform of AIF, AIF2, whose expression increases as neuronal 
precursor cells differentiate. AIF2 arises from the utilization of the alternative exon 2b, yet uses 
the same remaining 15 exons as the ubiquitous AIF1 isoform. AIF1 and AIF2 are similarly 
imported to mitochondria where they anchor to the inner membrane facing the intermembrane 
space. However, the mitochondrial inner membrane sorting signal (IMSS) encoded in the exon 
2b of AIF2 is more hydrophobic than that of AIF1, indicating a stronger membrane anchorage of 
AIF2 than AIF1. AIF2 is more difficult to be desorbed from mitochondria than AIF1 upon 
exposure to non-ionic detergents or basic pH. Furthermore, AIF2 dimerizes with AIF1, thereby 
preventing its release from mitochondria. Conversely, it is conceivable that a neuron-specific 
AIF isoform, AIF2, may have been "designed" to be retained in mitochondria and to minimize its 
potential neurotoxic activity.  
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Introduction 
Apoptosis-inducing factor (AIF) has initially been described as a mitochondrial intermembrane 
protein that is released from mitochondria under conditions of cell death induction and that can 
induce isolated nuclei to undergo nuclear shrinkage and chromatinolysis, two features that are 
classically associated with apoptosis.1 Since its discovery ten years ago, the AIF protein has been 
characterized at the structural level,2,3 and the AIF gene has been subjected to genetic 
manipulations in mice, flies, nematodes and yeast, revealing the phylogenetically conserved 
contribution of AIF to cell death in multiple systems.4,5  
 
After the mitochondrial import of the precursor AIF protein and the removal of its N-terminal 53 
amino acids, which includes a mitochondrial localization sequence (MLS), the processed mature 
human AIF 62-kDa is inserted into the inner mitochondrial membrane, with the N-terminus 
facing the matrix and with the C-terminal catalytic domain exposed to the intermembrane space.6 
The mitochondrial AIF protein is an NAD(P)H oxidase7 whose local redox function is essential 
for optimal oxidative phosphorylation.8 Knockdown, deletion or hypomorphic mutation of AIF 
(the harlequin or Hq mutation) reduces the expression of complex I subunits in the respiratory 
chain,8 thereby provoking a mitochondriopathy that leads to progressive neurodegeneration, 
photoreceptor loss and cardiomyopathy.9-13 The consistent finding that the targeting of AIF 
mostly affects the central nervous system (CNS)9 might either be explained by the general 
tendency of complex I mitochondriopathies to manifest at the level of the CNS14 and/or by an 
implication of AIF in the differentiation of neuronal cell precursors.12 
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Upon apoptotic stimuli, AIF, which is able to directly interact with DNA,15 translocates to the 
nucleus and participates in chromatin condensation and chromatinolysis.16 The switch from the 
vital to the lethal functions of AIF is spatially regulated by its subcellular localization and tightly 
controlled by at least two processes:  (i) outer mitochondrial membrane permeabilization 
(MOMP), which is regulated by multiple mitochondrial proteins including members of the Bcl-2 
family,17 (ii) activation of a series of non-caspase cysteine proteases (including calpains and 
cathepsins) that cleave the N-terminal membrane insertion domain at amino acid 101, thus 
catalyzing the de-attachment of mature AIF from the inner mitochondrial membrane.5,6,18The 
nuclear translocation of AIF could be inhibited by the overexpression of heat shock protein 70, 
which can intercept AIF in the cytosol19 or deletion of cyclophilin A, which is required for AIF 
to move into the nucleus.20 In mice, the Hq mutation has been shown to reduce acute neuronal 
cell death after ischemia, hypoglycemia and neurotrauma in young animals, before they manifest 
the Hq-associated neurodegeneration.21 However, the Hq mutation had no cardioprotective 
effect13 and was not able to make islet beta cells more resistant to hydrogen peroxide-induced 
cell death,22 suggesting that AIF contributes to lethal signaling in a cell type-specific fashion.  
 
Through alternative splicing, the precursor mRNA transcribed from the AIF gene can give rise to 
several distinct proteins. Thus, alternative utilization of the exons 2a or 2b of the AIF gene (16 
exons in total) gives rise to AIF1 (the originally described isoform of AIF) or AIF2 (which has 
been found in cDNA libraries from fetal mouse tissues), respectively. AIF1 and AIF2 only differ 
in a short stretch of their amino acid sequence in the N-terminal region that is removed from the 
mature protein as it translocates to the nucleus.23 Numerous functional studies have been 
performed on AIF1, the most abundant and ubiquitous AIF isoform, whereas, AIF2 has not been 
further characterized. In addition to the above-mentioned isoforms, an alternate transcriptional 
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start site located at intron 9 of AIF originates a short variant of the protein (AIFsh) that lacks the 
N-terminal MLS and the redox-active domain, yet retains the nuclear localization sequence 
(NLS). The transfection-enforced overexpression of AIFsh results in a nuclear protein that 
causes apoptosis.24 Moreover, another short form of AIF, AIFsh2, results from the alternative 
utilization of exon 9b (instead of 9), which contains a stop codon. AIFsh2 is a truncated protein 
that lacks the C-terminal pro-apoptotic domain, yet conserves its mitochondrial localization and 
redox function.25 Both short AIF isoforms appear to be low-abundant in normal tissues because 
they have not been detected by immunoblot, with the exception of AIFsh2 that reportedly is 
present in liver extracts.24,25 
 
By characterizing the tissue expression profile of AIF isoforms, we discovered that AIF2 is 
specifically expressed in the CNS. Driven by the pathophysiological impact of AIF in 
neurodegeneration,9,11,12 we performed an exhaustive functional and biochemical characterization 
of the AIF2 isoform and importantly, we found that, compared to AIF1, AIF2 possess a stronger 
anchoring capacity to the inner mitochondrial membrane. These results suggest that the neuron-
specific AIF2 isoform has been "designed" for maintaining its mitochondrial functions yet 
reducing its pro-apoptotic activities.  
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Results and Discussion 
A novel brain-specific isoform of AIF, AIF2. When sequencing several cDNAs from fetal 
human brain, we detected an alternative exon2 usage (Fig. 1a), indicating that the precursor of 
the human AIF mRNA can be alternatively spliced, yielding two isoforms that we designated 
AIF1 (when exon 2a is used) and AIF2 (when exon 2b is used). The alternative exons 2a and 2b 
are phylogenetically conserved among mammals. Likewise, the two exons were generated by 
gene duplication well before the speciation of mammals (data not shown). Indeed, we were able 
to trace the duplication event to chicken genome, where a region homologous to the mammalian 
exon 2a can be found 5' of exon 2b on chromosome 4, although the splice acceptor site of exon 
2a seems to be non canonical (UCSC, genome browser). Thus, both exons 2a and 2b are 
detectable in published cDNA sequences from primates, rodents and other mammals (such as 
Equus caballus and Canis familiaris) (NCBI-Homologen database), whereas only one exon 2, 
which resembled exon2b from mammals, could be discerned in chicken cDNA libraries (Fig. 1b, 
c). Amino acid alignments of exons 2a and 2b from several animal species revealed two 
positively- and one negatively-charged common residues, as well as conserved motifs with 
hydrophobic stretches (Fig. 1c). However, secondary structure predictions indicate the 
consequences of variable residues and their differential properties on the potential secondary 
structure of the segment encoded by each of the two exons (Fig. 1d). 
 
Quantitative expression profiling of the two AIF isoforms showed that AIF2 mRNA was 
specifically detected in human brain, yet was absent from most other analyzed tissues except the 
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retina (Fig. 2a). Within the human adult brain, AIF2 mRNA was found in all regions, including 
the cortex or in subcortical areas, and the expression level of AIF1 and AIF2 mRNAs were 
similar (Fig. 2b). This general expression profile was similar for all examined mouse tissues, 
where AIF2 mRNA was again restricted to the brain (Fig. 2c). Both in human and mice, low 
levels of AIF expression were detected in the brain compared to other organs. This probably 
reflects the comparative paucity of mitochondria in the brain, because the ratio of AIF protein 
and the most abundant outer mitochondrial membrane protein, VDAC, is similar in a panel of 
distinct mouse organs including brain14. The expression levels of AIF1- and AIF2-specific 
mRNAs were equivalent in the adult mouse brain and were similarly affected by the 
hypomorphic Hq mutation that reduced the expression of both AIF1 and AIF2 to around 20% of 
the control level (Fig. 2d). Of note, the expression of human AIF2 mRNA was higher in adult 
brain than in fetal brain (while that of AIF1 was lower) (Fig. 2b), indicating that the AIF1/AIF2 
ratio decreases as brain cells differentiate. Accordingly, mouse embryonic telencephalic cells 
immortalized with thermosensitive SV40 large T antigen (tsA58 LT-Ag) (Fig. 3a, b), or human 
embryonic mesencephalic cells immortalized with a v-Myc retroviral vector (Fig 3c) could be 
stimulated to express higher AIF2 levels upon in vitro differentiation. Thus, AIF2 is specifically 
and differentially expressed in brain cells, depending on their maturation status.  
 
Next, we determined the relative AIF1 and AIF2 mRNA expression in the NCI (National Cancer 
Institute) panel of cancer cell lines (NCI60). While AIF1 was expressed by all cells, 
independently of their tissue origin, AIF2 was absent from all samples (supplemental Fig. 1), 
including from brain cancer cell lines, of glial origin, contained in the NCI panel (Fig. 4a). 
However, AIF2 was expressed by a fraction of neuroblastomas (Fig. 4a and b), in line with the 
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data obtained on normal, untransformed tissues (see above, Fig. 2). In conclusion, AIF2 is 
specific for neuronal tissues and neuroblastomas.  
 
Cellular and subcellular localization of AIF2. Comparative in situ hybridizations of the adult 
mouse brain with isoform-specific probes revealed a similar macroscopic distribution of AIF1 
and AIF2 mRNAs, with peak intensities in the olfactory bulb, rostral migratory stream, olfactory 
cortex and pituitary (Fig 5a-f, negative controls with anti-sense probes are shown in 
Supplemental Fig. 2). To investigate whether both AIF isoforms are expressed in the same cells, 
we performed a simultaneous fluorescent in situ hybridization (FISH) with differentially labeled 
exon 2a- and 2b-specific probes (red and green, respectively). In most brain regions, AIF1 and 
AIF2 were co-expressed by the same cells. However, approximately 25% of the cells present in 
the anterior olfactory nucleus stained uniquely for the exon 2b-specific probe, indicating the 
existence of brain cells that solely express AIF2 (and not AIF1) (Fig 5g-i).  
 
AIF1 and AIF2 share an identical N-terminal MLS, while their exon 2-encoded inner membrane-
sorting signals (IMSS) differ (Fig 1). In order to investigate whether this difference might affect 
the mitochondrial localization of AIF2, we compared the subcellular distribution of AIF1 and 
AIF2 by transfecting Hela cells with Flag-tagged versions of AIF1 or AIF2 (with the Flag fused 
to the C-terminus). When transfected cells were fixed and permeabilized with paraformaldehyde 
plus Triton X100 and stained with a Flag-specific antibody (Fig. 6a), we found both proteins 
similarly redistributed into mitochondria (which were labeled with a matrix-targeted fluorescent 
protein, dsRed-mito), with no discernible effects on the overall shape of the mitochondrial 
network. Differential permeabilization of the outer mitochondrial membrane (with 0.4 mg/ml 
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digitonin) and the inner membrane (with 0.8 mg/ml digitonin) allowed antibodies specific for 
Tim23 (an inner membrane-anchored protein) and cyclophilin D (a soluble matrix protein), 
respectively, to access mitochondria (Fig. 6b). In these conditions, a Flag-specific antibody 
gained access to AIF1 and AIF2 similarly, as soon as the outer mitochondrial membrane was 
permeabilized (Fig. 6b, c), in concordance with the notion that both proteins expose their flagged 
C-termini to the intermembrane space.  
 
AIF-deficient cells exhibit reduced abundance of complex I subunits, resulting in a severe 
respiratory dysfunction.8 Accordingly, small interfering RNAs specific for exon 2a or the 3'UTR 
of AIF led to a marked reduction in the expression of the 20 kDa complex I subunit (CI SU20) 
(Fig. 6d) and other complex I subunits (not shown) in U2OS cells (which only express AIF1). 
The transfection of AIF2 (whose expression is not impeded by either of the two siRNAs) blunted 
the depletion of CI SU20 induced by AIF1 knockdown, as much as did the transfection of AIF1 
(whose overexpression is abolished by the exon 2a-specific siRNA, yet not affected by the 
3'UTR-specific siRNA) (Fig. 6d). These results corroborate the hypothesis that both AIF 
isoforms are localized in the same submitochondrial compartment where they both sustain the 
biogenesis or stability of complex I from the respiratory chain. It should be noted that the 
respiratory and redox functions of AIF are closely linked because redox-deficient AIF mutants 
are unable to restore the abundance and function of respiratory chain complex I from AIF 
knockout cell. 26 Therefore, it appears plausible that AIF2 has a normal redox function, similar to 
that of AIF1. Recently, Churbanova et al. 27 reported a rather low NAD(P)H oxidase activity for 
a recombinant AIF protein that resembles endogenous AIF more closely than a His-tagged, 
truncated protein that had been investigated  previously.7 In line with this possibility, we found 
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that the siRNA-mediated depletion of AIF1 and/or AIF2 from SHSY-5Y neuroblastoma cells 
(which express both AIF1 and AIF2) did not affect cellular NAD(P)H levels (Supplemental 
Fig.3).  
 
Biochemical differences between AIF1 and AIF2. In order to detect further possible differences 
between AIF1 and AIF2, we stably transfected the Flag-tagged versions of both proteins in 
U2OS cells, obtaining supraphysiological levels of AIF1 and AIF2 (Supplemental Fig. 4a). Both 
Flag-tagged AIF1 and AIF2 cDNAs led to the expression of proteins with a similar 
electrophoretic mobility corresponding to ~65 kDa (Supplemental Fig. 4a), and similar co-
migration results were obtained for non-tagged versions of AIF1 and AIF2 (not shown). The 
overexpression of AIF1 or AIF2 had neither deleterious effect on the proliferation rate (not 
shown), nor affected the respiratory capacity and control of the cells (Supplemental Fig. 4b). 
However, both AIF isoforms differentially affected the ultrastructure of mitochondria, as 
detectable by transmission electron microscopy (TEM). AIF1 (but not AIF2) overexpression lead 
to a rarefaction of cristae, while AIF2 (but not AIF1) overexpression tended to increase the 
curvature of cristae, which frequently adopted an onion-like shape (Supplemental Fig. 4c). 
Although this result was obtained in conditions in which the two AIF isoforms were 
overexpressed, it suggested subtle differences in the impact of the insertion of their putative 
transmembrane domains on mitochondrial membrane structure.  
 
Driven by these results, we investigated whether AIF1 and AIF2 actually differ in their 
membrane anchorage, in conditions in which Flag-tagged AIF1 and AIF2 are expressed at 
physiological levels (lower than endogenous AIF, Fig. 7a,b). AIF1 versus AIF2-expressing cells 
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were exposed to increasing concentrations of the non-ionic detergent Igepal CA-630, and the 
extractability of the two AIF isoforms was measured. While Igepal CA-630 efficiently extracted 
AIF1 from mitochondria, AIF2 was largely resistant to the detergent and remained bound to the 
ultra-centrifugable pellet. Thus, AIF2 behaves like the inner membrane-anchored CI SU20, while 
AIF1 behaved like several soluble mitochondrial proteins including cytochrome c (Fig. 7a). 
When, the Igepal CA-630 extraction protocol was replaced by a different one involving sodium 
carbonate, Flag-tagged AIF1 was again released in conditions of basic pH (pH=10.5), whereas 
Flag-tagged AIF2 remained attached to the membrane fraction (Fig. 7b). Importantly, in these 
conditions, endogenous AIF1 (the sole isoform of AIF expressed in HeLa cells) behaved like 
Flag-tagged AIF1, indicating that membrane-anchoring properties of the recombinant AIF was 
not affected by the Flag tag (Fig. 7b). Next, we assessed the effect of the alkylating agent MNNG 
on the release of AIF1 versus AIF2. Again, it appeared that Flag-tagged AIF1 was readily 
released into the cytosol of MNNG-treated cells, while Flag-tagged AIF2 remained attached to 
mitochondria (Fig. 7c). In these conditions, endogenous AIF1 co-translocated to the cytosol in 
the presence of Flag-tagged AIF1. However, endogenous AIF1 was withheld from the cytosol in 
the presence of Flag-tagged AIF2 (Fig. 7c).  
We conclude that AIF2 is more difficult to be released from mitochondria than AIF1. This 
difference cannot be explained by the consensus sequence of the cleavage site by calpains and 
cathepsins, which is the same for both proteins. Rather, the differential release of AIF1 and AIF2 
must be linked to other properties of the molecules such as the accessibility of AIF2 to proteases. 
Thus, the N-terminus of AIF2 might be more profoundly "buried" in the lipid bilayer of the inner 
mitochondrial membrane than that of AIF1. In support of this possibility, biochemical studies of 
AIF1 carried out by Churbanova et al.27 suggest that redox-regulated changes in the 
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conformation of AIF that implicate its N-terminal and C-terminal segments might dictate AIF’s 
accessibility to apoptotic proteases and regulate its mitochondrial release in dying cells. In this 
context, the dimerization of AIF molecules has also been suggested.27,28 Indeed, endogenous 
AIF1 could be detected in the anti-Flag immunoprecipitate of Flag-tagged AIF1 or AIF2 (Fig. 
7d). Thus, the two AIF isoforms can form homo- or heterodimers or higher-order oligomers. 
Accordingly, we hypothesize that the inhibitory effect of AIF2 on AIF1 release might be 
explained by a physical interaction between the two isoforms that makes the mitochondrial 
release-associated cleavage of AIF1 more difficult to be achieved when AIF2 is present. 
 
Concluding remarks  
In this paper, we comparatively analyze two AIF isoforms that solely differ in the utilization of 
one exon (exon 2) that codes for a portion of the AIF N-terminus. Both AIF isoforms, AIF1 and 
AIF2, are associated with the inner mitochondrial membrane and are similar in their capacity to 
sustain a normal function of the respiratory chain. Importantly, it appears that the IMSS of AIF1 
(IMSS-AIF1), which is encoded by exon 2a, is cleaved during the import of the AIF precursor 
into mitochondria, in a highly conserved peptide motif, after residue 54 (in humans AIF1) or 
residue 53 (in mouse AIF).6,29 This implies that only 29 amino acids of the C-terminal half of 
IMSS-AIF1 are present in the mature mitochondrial AIF1 protein. Importantly, mature 
mitochondrial AIF2 (as present in brain tissues or obtained by transfection with a cDNA) 
exhibited exactly the same electrophoretic mobility as AIF1, suggesting that AIF2 is trimmed 
during mitochondrial import by a peptidase that cleaves within the exon 2b-encoded IMSS-AIF2 
as well. As a result, the N-terminus of AIF1 and AIF2 are dissimilar in their primary sequence as 
well as in their hydrophobicity, explaining the relatively loose association of AIF1 (which bears 
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a less hydrophobic N-terminus than AIF2) with the inner mitochondrial membrane. 
Consequently, AIF2 is more difficult to dissociate from mitochondrial membranes, irrespective 
of the nature of the desorbing agent (non-ionic detergents, basic pH or MNNG stimuli), 
suggesting that AIF2 contributes less efficiently to apoptosis than AIF1.  
 
AIF2 was solely expressed in the developing and adult central nervous system (CNS), as well as 
in the retina (which contains neurons and, in developmental and anatomical terms, is a CNS 
derivative). Similarly AIF2 was present in neuroblastomas but not in any other kind of tumor 
derived from non-neuronal tissues. While all CNS cells that express AIF1 also contain AIF2, 
some cells whose exact nature remains to be identified are positive for AIF2 but not for AIF1. 
What might be the "purpose" of CNS-restricted expression of AIF2 in teleological terms? AIF1 
and AIF2 share their vital functions with regard to mitochondrial respiration, while AIF2 is more 
tightly bound to mitochondrial membranes and hence less likely to mediate cell death (which 
requires the mitochondrial release and nuclear translocation of AIF). If this hypothesis was 
correct, the utilization of exon 2b (which gives rise to AIF2) might constitute a strategy to avoid 
AIF-dependent neurotoxicity. Since AIF1 and 2 can interact with each other and since AIF2 can 
withhold AIF1 in mitochondria, the putative neuroprotective function of AIF2 would extend to 
those cells that express both AIF1 and AIF2. For testing this hypothesis, exon 2b-specific 
knockouts should be generated and evaluated for their putative neurotoxicity alone or upon 
neuronal injury. As a caveat, it must be mentioned that the expression level of AIF has a 
profound impact on neuronal differentiation.12 Therefore, it remains formally possible that AIF2 
(but not AIF1) is intimately linked to CNS development and that the exon 2b-specific knockout 
will cause major brain defects. These intriguing hypotheses will be studied in the future.  
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Materials and Methods 
Antibodies : The following antibodies were used: anti-actin mouse mAb (CHEMICON, 
MAB1501); anti-AIF mouse mAb (Santa Cruz, Sc13116); anti-CI SU20 (NDUFB8) mouse mAb 
(Mitosciences, MS105); CypD  mAb (Mitosciences, MSA04); anti-cytochrome C mouse mAb 
(Pharmingen, 556433); anti-Hsp60 mouse mAb (Stressgen, SPA-806); antiEndoG rabbit pAb 
(Cell Signaling, 4969); anti-Flag M2 mouse mAb (SIGMA, F3165); anti-Tim23 mAb (BD 
Transduction, 611222); polyclonal anti-VDAC rabbit pAb (Cell Signaling, 4866); HRP-
conjugated goat anti-mouse (Southern Biotech, 1031-05) and goat anti-rabbit (Southern biotech, 
4010-05); Alexa fluor 488-conjugated goat anti-mouse (Molecular probe, A11029). 
 
Plasmids and siRNA: Recombinant plasmids pCMV-AIF1-3xFlag and pCMV-AIF2-3xFlag 
were constructed by cloning AIF1 and AIF2 open reading frames between EcoR1 and kpn1 sites 
of the vector pCMV-3xFLAG-CMV-14 (Sigma). The plasmid dsRedmito (Clontech) 
overexpressing a mitochondrion-targeted dsRed fluorescent protein was used for the tagging of 
mitochondria in transfected cells. The reference plasmid (Ref-AIF1/AIF2) used for the relative 
quantitation of AIF1 and AIF2 expression level by standard curve method was constructed by 
simultaneous head-to-tail ligation of AIF1 (1 to 438 bp) and AIF2 (1 to 426 bp) open reading 
frames and their cloning into Not1 and EcoR1 sites of pGEMTeasy vector (Promega). For RNA 
interference experiments the following siRNA sequences were used: Negative control (C-) 
(AUGCAGAACUCCAAGCACGdTdT), AIF-exon 2a (GGGCAAAAUCGAUAAUUCUdTdT), 
and AIF 3’UTR (GCAGACUUUCUCUGUGUAUdTdT). 
 
 17     
Cell culture and transfection: Human Osteosarcoma U2OS cells (ATCC n°HTB-96) as well as 
cervix carcinoma Hela cells (ATCC n°CCL-2) were cultured at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (PAA) and 1% penicillin/streptomycin. Mouse embryonic fibroblasts (MEF) were 
cultured in Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% heat-
inactivated FBS (PAA), 1% penicillin/streptomycin (Invitrogen) and 0.01% β-mercaptoethanol. 
Mouse neural precursor cells (ETNA) were cultured and differentiated in vitro according to 
Cozzolino et al.30 LUHMES (Lund Human Mesencephalic neurons) that were derived by 
conditional immortalization of female human embryonic ventral mesencephalic cells and 
subsequent clonal selection, could be differentiated in the presence of GDNF into postmitotic 
neurons with a robust dopaminergic phenotype.31 Briefly, LUHMES were cultured in poly-L-
lysine (Sigma) and fibronectin (Sigma) (50µg/ml)-coated culture flasks in proliferation medium, 
namely DMEM/F12 (Sigma) supplemented with 2 mM L-glutamine (Invitrogen), 1% N2 
supplement, 25µg/ml bFGF (R&D Systems) and 1% penicillin/streptomycin (Invitrogen). Cells 
were cultured at a density of 2 x 106 and split every 4 or 5 days with proliferation medium 
changes every 3 days or at 80% confluence. For differentiation, cells were seeded in 6 well plates 
at a density of 40.000 cells/cm2 in differentiation medium, namely DMEM/F12, 1% N2 
supplement, 1 mg/ml tetracyclin (Sigma), 49 mg/ml dibutyryl-cAMP (R&D Systems), and 5 
ng/µl GDNF (R&D Systems). Every day and up to 6 days after the onset of differentiation, 6 
wells were pooled for RNA extraction. 
Plasmid and siRNA transfections were performed using Lipofectamine-2000 reagent 
(Invitrogen) by following manufacturer’s procedure.  Pools of stably transfected U2OS cells 
expressing AIF1-Flag or AIF2-Flag were established by co-transfection with the plasmids 
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described above and the pPuro plasmid (Clontech) followed by selection in the presence of 0.25 
µg/ml of puromycin (Clontech) and 0.5 mg/ml of Geneticin (Invitrogen).  
 
Cell lysates preparation, immunoprecipitation and Western blot analyses: For whole extract 
preparation, cells were harvested, washed three times with ice-cold PBS (8.1 mM Na2HPO4, 135 
mM NaCl, 1.5 mM KH2PO4, 2.7 mM KCl), lysed with 1% SDS, boiled, sonicated, and stored at -
80°C. Proteins contained in the lysate were quantified (DC protein assay; Biorad) and resolved 
directly by SDS/PAGE (NUPAGE; Invitrogen) and then subjected to Western blot analyses 
following manufacturer reagents and instructions (Invitrogen). For immunoprecipitations, cells 
were lysed for 20 minutes at 4°C in the following buffer: NetN-120 (20 mM Tris-HCl at pH 8.0, 
120 mM NaCl, 1 mM EDTA, 0.5 % Igepal CA 630) supplemented with protease (EDTA-free 
protease inhibitor tablets - Roche) and phosphatase (Phosphatase inhibitor tablets - Roche) 
inhibitors. After centrifugation (13,000xg  for 10 min at 4°C), the protein content in the lysates 
was quantified and used for immunoprecipitations. The following immunoprecipitation 
procedure was used: first protein G-Sepharose CL-4B beads (50 µl of a 50 % slurry, GE 
Healthcare) were coated with 1 µg of the indicated antibody, by incubating for 2 h at 4°C in 800 
µl of binding buffer (20 mM Tris-HCl pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.5 % Igepal). 
Then, antibody-coated beads were washed three times in binding buffer and incubated for 2 h at 
4°C with 300 µg of cell lysate, in a final volume of 800 µl. Beads were finally washed four times 
with lysis buffer and co-immunoprecipitated proteins were released by boiling in SB (2 % SDS, 
10 % glycerol, 62.5 mM Tris-HCl pH 6.8, 100 mM dithiothreitol), resolved by SDS/PAGE and 
then subjected to Western blot analysis. For Western blot analysis, SDS/PAGE-resolved proteins 
were transferred onto nitrocellulose membrane (Biorad). Membranes were blocked by incubating 
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with 5% nonfat milk powder in TBST buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05 % 
Tween 20) for 1h, and then for further 16 h at 4°C with the specified primary antibody diluted in 
the same incubation mixture supplemented with 0.02% Na-azide. The membrane was then 
washed three times in TBST buffer before incubation with a horseradish peroxidase-conjugated 
secondary antibody. Antibody binding was detected with the ECL+ chemiluminescence 
detection kit (GE Healthcare). 
 
Indirect immunofluorescence analyses: Cells were fixed on coverslips for 30 min with 4% PFA 
/2% Sucrose/0.19% Picric acid, then permeabilized for 5 min with Triton 0.2% at room 
temperature. Flag-tagged proteins were detected by incubation with an anti-Flag mAb (1:8000 
dilution), followed by Alexa fluor 488-conjugated goat anti-mouse. We stained the DNA in the 
samples with 1 µM TOPRO3 (Invitrogen). Samples slides were then mounted using the reagent 
Fluoromont-G (Southern Biotech) and observed by confocal microscopy with a Leica TSC-SPE 
confocal microscope equipped with a 63x/1.15 Olympus objective and a Leica Aplication Suite 
(LAS) software (Leica Microsystems). For the submitochondrial localization of AIF2, pools of 
stably transfected U2OS cells overexpressing AIF1-Flag ou AIF2-Flag were first fixed for 30 
min with 4% PFA /2% Sucrose/0.19% Picric acid then permeabilized for 5 min without or with 
0.4 and 0.8 mg/ml of digitonin. Flag-tagged proteins were detected by incubation with an anti-
Flag mAb (1:8000 dilution), followed by a Alexa fluor 488-conjugated goat anti-mouse. Anti-
Tim23 mab and CypD mab were used for the detection of respectively mitochondrial inner 
membrane and matrix. DNA in the samples was stained with TOPRO3. Samples were then 
mounted and observed with a Leica TSC-SPE confocal microscope. 
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RNA Isolation and gene expression analysis by quantitative real-time PCR (qRT-PCR): Total 
RNA purified from normal human organs or brain sub-regions were purchased from Clonetech. 
Total RNA from wild type (wt) or harlequin (Hq) mutant mice organs were extracted using 
Precellys homogenizer (Bertin) and RNA isolation kit from Qiagen. RNA from human and 
mouse cells in culture were extracted using PARIS kit (Ambion) or  “Total RNA Isolation Kit II” 
(Macherey Nagel). All RNA samples were then stored at -80°C. The quantification of RNA 
samples was achieved using the Nanodrop ND-1000 Spectrophotometer and the integrity of the 
RNA was verified using the Agilent 2100 Bioanalyzer with the Eukaryote Total RNA Nano 
assay. One microgram of total RNA was reverse-transcribed in a 20µl final reaction volume 
using the High Capacity cDNA Reverse Transcription Kit with RNase inhibitor (Applied 
Biosystems) following the manufacturer’s instructions. For the human and mouse AIF1 and 
AIF2, the following primers and Taqman MGB probes were custom-made by Applied 
Biosystems: human AIF1 primer (AIF1F): 5’GGCAAAATCGATAATTCTGTGTTAGTC3’; 
human AIF2 primer (AIF2F): 5’GGAAAGATGGCAGCAACCTAGTGTACT3’; human AIF 
commun primer (AIFcr): 5’CCACCAATTAGCAGGAAAGGAA 3’; human AIF commun probe 
(AIFcp): 5’ TGTTTCTGTTCTGGTGTCAG 3’; mouse AIF1 primer (AIF1R): 
5’CCATTGCTGGAACAAGTTGC 3’; mouse AIF2 primer (AIF2R): 
5’CTAGGAGATGACACTGCACAA 3’; mouse AIF commun primer (AIFcF): 
5’CGAGCCCGTGGTATTCGA 3’; mouse AIF commun probe (AIFSc): 5’ 
ACGGTGCGTGGAAG 3’. TaqMan® probes were labeled with 6-FAM at the 5’ end and with a 
nonfluorescent MGB quencher at the 3’ end. Each probe was combined with different forward 
and reverse primers (see list) for AIF1 or AIF2 quantification. TaqMan® gene expression assays 
for 18S ribosomal RNA (Hs99999901_s1), GAPDH (Mm99999915_g1), PGK1 
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(Mm00435617_m1), TBP (Mm00446973_m1) and the TaqMan® Mouse Endogenous Control 
Arrays (384-well micro fluidic card containing 16 mouse TaqMan® Gene Expression Assays) 
were from Applied Biosystems. Quantitative PCR reactions were performed using ABI Prism 
7900 HT sequence detection system (Applied Biosystems). For microplate experiments, 25 ng of 
cDNA were used as template for q-PCR reactions with TaqMan® Universal Master Mix 
(Applied Biosystems), 900 nM primers and 200 nM probes. Real-time q-PCR amplifications 
were carried out (10 min 95°C followed by 45 cycles of 15 sec 95°C and 1 min 60°C). Technical 
replicates were performed for each biological sample. For the micro fluidic Taqman® arrays, 
100 ng of cDNA were used per sample-loading ports, each allowing 48 q-PCR reactions using 
manufacturer instructions (10 min 94.5°C followed by 40 cycles of 30 sec 97°C and 1 min 
59.7°C). For AIF1 and AIF2 expression quantification in differentiating mouse neural cells, 
reference genes were selected using the TaqMan® Mouse Endogenous Control Arrays. Briefly, 
16 housekeeping genes were tested in triplicate for each sample. The most stable genes were 
selected by analyzing results with GeNorm and Normfinder functions in Genex 4.3.8 (MultiD, 
Göteborg, Sweden). The geometric mean of the 3 best housekeeping genes (GAPDH, PGK1 and 
TBP) was used to normalize gene expression levels of AIF1 and AIF2 for further analysis of 
microplate q-PCR experiments with the relative quantification method. For AIF1 and AIF2 
expression quantification in human samples, absolute quantification experiment were performed 
using standard curves obtained by a ten-fold dilution series of a pBlueREF-AIF1+2 plasmid. 
Obtained Ct values for each human sample allowed AIF1 and AIF2 quantifications according to 
the standard curves using SDS 2.3 software (Applied Biosystems). Determined quantity values 
were then exploited for further analysis. 
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Mice manipulation: Wild type male CD-1 mice of 3-5 months age were used for the in situ 
hybridization experiments. Animals were anesthetized with Avertin (0.25 mg/g body weight, 
intraperitoneally) and perfused through the heart sequentially, first with PBS (pH 7.4) and then 
with 4% paraformaldehyde (PFA). The brains were post-fixed for 24 h at 4°C and cryoprotected 
with 30% sucrose/PBS for 48 h at 4°C. Coronal and sagittal cryosections (18-20 µm thick) were 
obtained by using a cryostat and collected at -80°C. 
 
In situ hybridization: The cDNA fragments of mouse AIF1 and AIF2 isoforms (NM_012019 
and CX_238424) were obtained by RT/PCR from total RNA extracted from adult mouse brain, 
using the following primers: AIF1 forward 5’-GCAACTTGTTCCAGCAATGGC-3’ and reverse 
5’-gcaccagctcctattgttgataagc-3’; AIF2 forward 5’-GCAGTGTCATCTCCTAGGATC-3’ and 
reverse 5’-ATAAATTCCTGCCCCAGTCAC-3’. Different cDNAs were subcloned into the 
pGemT-easy vector (Promega). The digoxigenin (DIG)- and biotin (BIO)-labeled riboprobes 
were produced using these plasmids as templates for the in vitro transcription according to the 
manufacturer’s instructions (Roche). Cryosections were fixed in 4% PFA for 15 min, then 
treated with proteinase K (20 µg/ml) and with 0,2% glycine for 5 min, respectively. A second 
fixing with 4% PFA and 0,2% glutaraldehyde was followed. The sections were pre-hybridized at 
55°C for 2 h in the hybridization buffer (50% formamide, 5x SSC, 10% blocking reagent, 5mM 
EDTA, 0.1% Tween-20, 0.1% CHAPS, 0.1mg/ml heparin, 1mg/ml yeast RNA). The probes 
labeled with digoxigenin (DIG) or biotin (BIO) were added to the hybridization mix at 
concentrations of 1ng/µl and 15 ng/µl in the colorimetric and fluorescence in situ hybridization, 
respectively. The sections were incubated with this solution at 55°C over night. The sections 
were sequentially washed in 2x SSC/50% formamide at 50°C, three times for 30 min, and then in 
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PBS at room temperature. In the colorimetric in situ hybridization, alkaline phosphatase-
conjugated anti-DIG antibody and the chromogenic substrate NBT/BCIP were used to detect the 
DIG-labeled probe, according to the manufacter’s protocol (Roche). Images were captured using 
a Nikon SMZ 800 microscope equipped with Nikon Coolpix 995 digital camera. In the 
fluorescence in situ hybridization, the sections were incubated with the anti-DIG antibody 
conjugated with Cy3 at concentration of 1:100 (Jackson Immunoresearch) for 2 h at room 
temperature for the detection of the DIG-labeled probe. After three washes in PBS, the sections 
were incubated for 30 min at room temperature with the streptavidin conjugated with Alexa488 
at concentration of 1:100 (Invitrogen) to detect the BIO-labeled probe. There were no apparent 
signals in control sections with the sense probes. The fluorescence was acquired by using a 
confocal laser scanning microscope (Leica). The brightness and contrast were adjusted using 
LAS software (Leica Microsystems).  
 
Differential Mitochondrial membrane permeabilization using with non ionic detergent: Mouse 
embryonic fibroblasts (MEF) transiently overexpressing AIF1-Flag or AIF2-Flag were incubated 
for 30 min in buffer A (20 mM Tris pH8, 120 mM NaCl, 1 mM EDTA) or buffer A 
supplemented with 0.03% - 0.06% - 0.1% of Igepal CA-630 (Sigma). Membrane-bound proteins 
were separated from soluble proteins by 10 min centrifugation at 13 000 g and analyzed by 
Western blot.  
 
Mitochondria purification: Cells were incubated for 20 min in a hypotonic buffer (10 mM 
Hepes-KOH, pH 7.9 ; 1.5 mM  MgCl2; 10 mM KCl ; 0.5 mM  DTT) supplemented with protease 
and phosphatase inhibitors (1 tablet/10ml, Roche). Cells were then lysed with a Dounce 
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homogenizer and centrifuged for 10 min at 700 g. The corresponding supernatant was transferred 
to a fresh tube and centrifuged for an additional 15 min at 12 000 g. The pellet, which 
corresponded to the mitochondrial fraction, was washed 1x with the hypotonic buffer and lysed 
with 1% SDS.  
 
Mitochondrial membrane solubilization at high pH (Na2CO3 treatment): Mitochondria were 
purified from Hela cells transiently overexpressing AIF1-Flag or AIF2-Flag as described above. 
The post-centrifugation mitochondria-enriched pellet was resuspended and incubated for 20 min 
in 100 mM Na2CO3  (pH 10,5) and then centrifuged for 1h at 65000 rpm. Solubilized proteins 
contained in the supernatant (S) and those still bound to membranes contained in the pellet (P) 
were lysed 1% SDS (diluted in 100 mM Na2CO3, pH 10.5) and analyzed by Western blotting. 
 
Membrane/Cytosol fraction separation: Hela cells overexpressing AIF1-Flag or AIF2-Flag 
were incubated for 20 min in a hypotonic buffer (10 mM Hepes-KOH pH 7.9; 1.5 mM MgCl2; 
10 mM KCl and 0.5 mM DTT) supplemented with protease and phosphatase inhibitors. Cells 
were then lysed with a Dounce homogenizer and centrifuged for 15 min at 12 000 g. The pellet, 
corresponding to the membrane fraction, was washed 1x with the hypotonic buffer before being 
lyzed in the same buffer supplemented with 1% SDS. The supernatant was re-centrifuged at 
65000 rpm for 1h supplemented with 1% SDS and used as the cytosolic fraction. To study the 
mitochondrial release of AIF1 and AIF2 after treatment with MNNG (N-Methyl-N'-Nitro-N-
Nitrosoguanidine), Hela cells were treated for 15 min with 500 µM before being re-incubated at 
37°C with the complet drug-medium for 4 hr and processed for membrane/ cytosol fractionation.  
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Assessment of respiratory chain function: A first spectrophotometric assay was used to 
successively measure the activity of complex IV (cyanide-sensitive cytochrome c oxidase), 
complex II+III (malonate-sensitive succinate cytochrome c reductase) and complex III 
(antimycin-sensitive decylubiquinol cytochrome c reductase) in 400 μl of medium containing 10 
mM KH2PO4, pH 7.2) and 1 mg/ml BSA.32 This assay measures the redox changes of 
cytochrome c using two wavelengths (550 nm–540 nm). A second assay successively measuring 
the activity of complex I (rotenone-sensitive decylubiquinone NADH reductase) and V 
(oligomycin-sensitive ATPase) was performed in 320 μl of water to which is added 80 μl of 
medium consisting of 50 mM Tris (pH 8.0), and 5 mg/ml BSA. It measures NADH oxidation at 
wavelengths of 340 nm–380 nm as previously described.32 All measurements were carried out 
using a Cary 50 spectrophotometer equipped with an 18-cell holder maintained at 37 °C. All 
chemicals were of the highest grade from Sigma Chemical Company (St Louis). 
 
Electron Microscopy: Cells were fixed in phosphate buffer pH 7.2 - 3% glutaraldehyde for 1 h, 
and postfixed in 0.1M cacodylate buffer  – 1% osmium tetroxyde for 2 h. After being rinsed for 5 
min in water and 15 min in the 0.1M cacodylate buffer, cells were transferred to 0.2 M 
cacodylate buffer for 30 min. Cells were washed in 30% methanol for 10 min, stained in 2% 
uranyl acetate in 0.1M cacodylate buffer – 30% methanol for 1 h, and washed in 30% methanol. 
Cells were then dehydrated in increasing concentrations of ethanol and embedded in Epon 812. 
For observations, ultrathin sections were contrasted with 4% uranyl acetate and lead citrate and 
examined with a FEI Technaï 12 microscope at 80 Kv.33 
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1: Comparison of AIF1 and AIF2 sequences. (a) AIF1 and AIF2 are alternative 
splice variants transcribed from AIF locus. Alternative usage of exon-2a or -2b of AIF gene 
allows the synthesis of respectively AIF1 and AIF2 isoforms. Human AIF1 and AIF2 share an 
identical N-terminal (aa 1-35) mitochondrial localization signal (MLS) but bear different inner 
membrane sorting signal (IMSS-AIF1: aa 35-82 and IMSS-AIF2: aa 35-78) encoded respectively 
by exon-2a and -2b. The rest of the protein is identical for both isoforms. Primary amino acid 
sequence comparison for MLS and IMSS regions of AIF1 and AIF2 was achieved using 
DNASTAR multiple alignment program. Residues differing between the two isoforms are 
colored in red. (b) Phylogenetic analyses of AIF1 and AIF2. Mutiple alignment of exon 2-
encoded polypeptides, available from public databases, reveals a restricted simultaneous usage of 
exon-2a and -2b to mammals. Chicken AIF protein is rooted to mammalian AIF2. This tree is 
obtained using neighbor joining method after clustalW multiple alignment. Refseq identifiers for 
analyzed protein sequences are the followings:  Homo sapiens AIF1 (NP_004199), AIF2 
(NP_665811); Macaca mulata AIF1 (XP_001092146), AIF2 (XP_001092025); Equus Caballus 
AIF1 (XP_001915191), AIF2 (XP_001915198); Canis familiaris AIF1 (XP_538170), (AIF2 
XP_865808); Mus musculus AIF1 (NP_036149), AIF2 (CAM22220); Rattus norvegicus AIF1 
(NP_112646), AIF2 (EDM10916); Gallus gallus AIF (NP_001007491). (c) AIF1-IMSS and 
AIF2-IMSS share conserved amino acids. Multiple alignment of exon-2a-encoded against 
exon-2b-encoded polypeptide segments, from the same organisms presented in 1b, was achieved 
using clustalW multiple alignment program. Star indicates fully conserved residues. Dots 
indicate residues with similar properties. The histogram of residue conservation is presented at 
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the bottom of the figure. (d) Prediction of secondary structural characteristics and 
physicochemical properties of the N-terminal segments of AIF1 and AIF2. Entire primary 
amino acid sequences of AIF1 and AIF2 were analyzed using DNASTAR Protean Secondary 
structure prediction program and only the result for the N-terminal segment (MLS + IMSS) of 
each isoform is shown.  
 
Figure 2: AIF2 mRNA expression is restricted to the brain. Quantitative expression analyses 
of AIF1 and AIF2 mRNAs in various human (a) and murine (c) organs or in various human 
brain sub-regions (b) were performed. AIF1 and AIF2 mRNA expression was compared between 
brains of wild type (wt) and hypomorphic Harlequin (Hq) mutant mice (d). Data obtained for 
human samples (a and b) correspond to three independent quantifications (mean + SD) and for 
mouse organs (c and d) represent means + SD from at least three independent experiments. 
Relative quantification of AIF1 and AIF2 mRNA expression levels in human samples (a, b) was 
achieved by standard curve method using an AIF1/AIF2 reference plasmid. For murine RNA 
samples, relative fold variation of AIF1 and AIF2 were calculated using the comparative Ct 
method.  
 
Figure 3: Expression of AIF2 during neuronal differentiation. Murine neural precursor cells 
(ETNA) were differentiated in vitro into neurons (a) (Bar represents 20 µm) and AIF1 and AIF2 
mRNA expression levels were compared between undifferentiated, solvent-treated and 
differentiated cells (b). Data represents three independent experiments (mean + SD). Human 
mesencephalic cells (LUHMES) were differentiated in vitro into postmitotic dopaminergic 
neurons and AIF1 and AIF2 mRNA expression levels were compared in RNA samples prepared 
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every day, from day 0 (undifferentiated) up to day 6 after the onset of differentiation (g). Data 
result from two independent quantifications (means + SD).  
 
Figure 4: AIF1 and AIF2 mRNA expression profile in cancer cells. Quantitative expression 
levels of AIF1 and AIF2 mRNAs were measured in human neurablastoma (IMR32, SHSY5Y 
and SK-N-AS) and glioblastoma (A172 and NCI60 panel: SF-268, SF-295, SF-539, SNB-19, 
SNB-75 and U251) cell lines (a) as well as primary human neuroblastoma tumors (b). Means + 
SD are obtained from two independent experiments.  
 
Figure 5: AIF1 and AIF2 mRNA expression pattern in mouse brain. (a-f) Parallel in situ 
hybridization using respectively AIF1 (a, c, e) and AIF2  (b, d, f) specific probes on brain 
sagittal sections (a and b) or the mitral and granular cell layers of the olfactory bulb (c and d) 
and cortex (e and f) on coronal sections (Bar =1 mm). (g-i) dual fluorescent in situ hybridization, 
with AIF1 (red) (g) and AIF2 (green) (h) probes, on the anterior olfactory nucleus (aon) area of 
brain in sagittal section. The arrows indicate positive cells only for AIF2 in merged images (i) 
(Bar=20 µm). aon, anterior olfactory nucleus; gl, glomerular layer; gro, granular cell layer; mi, 
mitral cell layer; tu, olfactory tubercle; pir, piriform cortex. 
 
Figure 6: (a) AIF2 is targeted to mitochondria. HeLa cells transiently co-transfected with the 
mitochondrial marker dsRed-mito (red fluorescence) and pCMV-AIF1-Flag (top panel) or 
pCMV-AIF2-Flag (bottom panel) were fixed, immunostained using an anti-Flag antibody 
(green), counterstained with the DNA-specific dye TOPRO3 for the determination of nuclear 
area and then observed by confocal microscopy; (b) AIF1 and AIF2 are localized in the same 
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sub-mitochondrial compartment. U20S cells stably overexpressing AIF1-Flag or AIF2-Flag 
were permeabilized with various concentrations of digitonin and mitochondrial proteins were 
detected using anti-Flag (AIF1-Flag and AIF2-Flag), anti-Tim23 (inner membrane protein 
Tim23) and anti-CypD (Matrix protein CypD) by confocal microscopy; (c) Histogram of the 
frequency of cells positively immunostained with each antibody for all permeabilization 
conditions used in (c); (d) Both AIF1 and AIF2 regulate mitochondrial respiratory chain 
complex I subunits.  Western blot analysis of complex I subunit CI SU20 (NDUFB8). Whole 
lysates of U20S cells cotransfected with control siRNA, or AIF siRNA (AIF exon2a or AIF 
3’UTR) in the presence of empty vector (Flag) or recombinant plasmid pCMV-AIF1-Flag 
(AIF1-Flag) or pCMV-AIF2-Flag (AIF2-Flag) were subjected to Western blot detection of 
indicated proteins. Bar =5 µm. 
 
Figure 7: Membrane anchorage capacity of AIF1 and AIF2. (a) Detergent-induced 
permeabilization of mitochondrial membranes. MEF cells transiently transfected with vector 
(Flag), pCMV-AIF1-Flag (AIF1-Flag) or pCMV-AIF2-Flag (AIF2-Flag) were incubated without 
or with increasing concentrations of Igepal CA-630 and then ultracentrifuged to separate the 
soluble fraction (Supernatant) from the membrane fraction (Pellet). Proteins in both fractions 
were separated by SDS-PAGE and then analyzed by Western blot using antibodies for the 
indicated proteins. (b) High pH-dependent mitochondrial membrane solubilization. 
Mitochondria were first purified from HeLa cells overexpressing AIF1-Flag or AIF2-Flag and 
then incubated with 100 mM Na-carbonate (pH 10.5). After centrifugation, supernatant (S) as 
well as pellet (P) fractions were subjected to SDS/PAGE and Western blot analyses using the 
indicated antibodies. (c) Mitochondrial release of AIF1 and AIF2 in MNNG treated cells.  
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HeLa cells overexpressing AIF1-Flag or AIF2-Flag were treated with DMSO or with the 
alkylating agent MNNG and then lysed under hypotonic buffer conditions. Cytosolic and 
membrane fractions obtained after high-speed ultracentrifugation were then subjected to 
SDS/PAGE and Western blot analyses using the indicated antibodies. (d) AIF1 and AIF2 
dimerization. HeLa cells transiently transfected with vector (Flag), pCMV-AIF1-Flag (AIF1-
Flag) or pCMV-AIF2-Flag (AIF2-Flag) were lysed and submitted to immunoprecipitation using 
the indicated antibodies. Whole cell lysates (Input) as well as co-immunoprecipitated proteins 
were then resolved by SDS-PAGE and submitted to Western blot analyses using the indicated 
antibodies. Arrows indicate the electrophoretic position of Flag-tagged and endogenous AIF 
proteins. 
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Supplemental figure informations 
 
A brain-specific isoform of mitochondrial Apoptosis Inducing Factor: AIF2 
Hangen et al. 
 
 
Supplemental figure 1: AIF1 isoform mRNA expression in NCI60 panel cancer cell lines.  
Quantitative expression analysis of AIF1 mRNA in NCI60 panel of human cancer cell lines, 
originated from various tissues, was achieved and relative fold variation of AIF1 in analyzed cell 
lines was calculated using the comparative Ct method. The 18S RNA was used as the 
endogenous reference. 
 
Supplemental figure 2: in situ hybridization controls. Results using control sense probes for 
AIF1 (a, c, e) and AIF2  (b, d, f) on brain saggital sections (a and b), the mitral and granular cell 
layers of the olfactory bulb (c and d) and cortex (e and f) on coronal sections is displayed. 
 
Supplemental figure 3: Failure of AIF depletion to affect NAD(P)H levels in neuroblastoma 
cells. Cytofluorometric determination of baseline levels of NAD(P)H  in SHSY-5Y 
neuroblastoma cells transfected with a control siRNAs or siRNAs that have been designed to 
deplete AIF1, AIF2 or both (same siRNAs as Fig. 6d). Then, the autofluorescence of cells 
(excitation 360 nM, emission 530 nm) was determined as an estimate of the intracellular 
NAD(P)H concentration. This experiment has been repeated three times, yielding similar results.  
 
Supplemental figure 4: Overexpression of AIF1-Flag and AIF2-Flag differentially affects 
mitochondrial ultrastructure. Untransfected U20S cells or pools of stably transfected cells 
with the empty vector (vector) or pCMV-AIF1-Flag (AIF1-Flag) or pCMV-AIF2-Flag (AIF2-
Flag) were analyzed for recombinant Flag-tagged AIF expression (a), the activity of 
mitochondrial respiratory chain complexes (CI to CV) (b) and mitochondrial ultrastructure by 
transmission electron microscopy (c). 
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